Literature DB >> 34053594

Alopecia Areata: New Treatment Options Including Janus Kinase Inhibitors.

Caiwei Zheng1, Antonella Tosti2.   

Abstract

Alopecia areata (AA) is a chronic, relapsing, autoimmune disorder characterized by patchy nonscaring hair loss. Although the pathogenesis of alopecia areata is not yet completely elucidated, loss of immune privilege in anagen stage hair follicles is widely accepted to play a key role. Several cytokines that depend on Janus kinase signaling have been identified to be involved in AA, including interleukin (IL)-2, IL-7, IL-15, IL-21, and interferon-γ, making Janus kinase inhibitors an attractive therapeutic target. Available information indicates that about 70% of patients with AA experience significant regrowth, but interruption of treatment is associated with disease recurrence.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Abatacept; Baricitinib; Platelet-rich plasma; Ruxolitinib; Tofacitinib

Year:  2021        PMID: 34053594     DOI: 10.1016/j.det.2021.03.005

Source DB:  PubMed          Journal:  Dermatol Clin        ISSN: 0733-8635            Impact factor:   3.478


  5 in total

1.  Economic Impact of Home-Use versus Office-Use Diphenylcyclopropenone in Extensive Alopecia Areata.

Authors:  Chinmanat Lekhavat; Pinyo Rattanaumpawan; Isree Juengsamranphong
Journal:  Skin Appendage Disord       Date:  2021-11-22

Review 2.  Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach.

Authors:  Yoshiya Tanaka; Yiming Luo; John J O'Shea; Shingo Nakayamada
Journal:  Nat Rev Rheumatol       Date:  2022-01-05       Impact factor: 32.286

Review 3.  Cognitive Process of Psoriasis and Its Comorbidities: From Epidemiology to Genetics.

Authors:  Jing Gao; Xue Shen; Randy Ko; Cong Huang; Changbing Shen
Journal:  Front Genet       Date:  2021-11-26       Impact factor: 4.599

Review 4.  The landscape of aging.

Authors:  Yusheng Cai; Wei Song; Jiaming Li; Ying Jing; Chuqian Liang; Liyuan Zhang; Xia Zhang; Wenhui Zhang; Beibei Liu; Yongpan An; Jingyi Li; Baixue Tang; Siyu Pei; Xueying Wu; Yuxuan Liu; Cheng-Le Zhuang; Yilin Ying; Xuefeng Dou; Yu Chen; Fu-Hui Xiao; Dingfeng Li; Ruici Yang; Ya Zhao; Yang Wang; Lihui Wang; Yujing Li; Shuai Ma; Si Wang; Xiaoyuan Song; Jie Ren; Liang Zhang; Jun Wang; Weiqi Zhang; Zhengwei Xie; Jing Qu; Jianwei Wang; Yichuan Xiao; Ye Tian; Gelin Wang; Ping Hu; Jing Ye; Yu Sun; Zhiyong Mao; Qing-Peng Kong; Qiang Liu; Weiguo Zou; Xiao-Li Tian; Zhi-Xiong Xiao; Yong Liu; Jun-Ping Liu; Moshi Song; Jing-Dong J Han; Guang-Hui Liu
Journal:  Sci China Life Sci       Date:  2022-09-02       Impact factor: 10.372

5.  Olumniant (Baricitinib) oral tablets: An insight into FDA-approved systemic treatment for Alopecia Areata.

Authors:  Eman Ali; Rabia Owais; Ayesha Sheikh; Asim Shaikh
Journal:  Ann Med Surg (Lond)       Date:  2022-07-13
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.